-transparent.png){kind=logo}
Prodrugs bioreductively activated to bleomycin analogues are reported. The production of hydroxyl radicals in the presence of FE(II) and dioxygen by both the prodrugs and the activated products are determined and their in vitro cytotoxicity measured.
Related Publications
J A Highfield, and
L K Mehta, and
J Parrick, and
L P Candeias, and
P Wardman
July 2023,
RSC medicinal chemistry,
J A Highfield, and
L K Mehta, and
J Parrick, and
L P Candeias, and
P Wardman
April 2016,
Nature protocols,
J A Highfield, and
L K Mehta, and
J Parrick, and
L P Candeias, and
P Wardman
May 2020,
Bioorganic chemistry,
J A Highfield, and
L K Mehta, and
J Parrick, and
L P Candeias, and
P Wardman
May 2017,
European journal of medicinal chemistry,
J A Highfield, and
L K Mehta, and
J Parrick, and
L P Candeias, and
P Wardman
December 2017,
Bioorganic & medicinal chemistry letters,
J A Highfield, and
L K Mehta, and
J Parrick, and
L P Candeias, and
P Wardman
May 2015,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J A Highfield, and
L K Mehta, and
J Parrick, and
L P Candeias, and
P Wardman
January 2021,
Frontiers in oncology,
J A Highfield, and
L K Mehta, and
J Parrick, and
L P Candeias, and
P Wardman
April 2019,
Chemistry, an Asian journal,
J A Highfield, and
L K Mehta, and
J Parrick, and
L P Candeias, and
P Wardman
October 1991,
Journal of medicinal chemistry,
J A Highfield, and
L K Mehta, and
J Parrick, and
L P Candeias, and
P Wardman
August 2003,
Bioorganic & medicinal chemistry letters,
